Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00544908 · ClinicalTrials.gov registry record · Phase 2
Dasatinib in Treating Patients With Stage IV Pancreatic Cancer
A Phase 2 study, sponsored by City of Hope Medical Center.
- Terminated
- Registry status
- Phase 2
- Development phase
- 7
- Enrollment target
NCT00544908: Clinical Trial Phase 2 study, sponsored by City of Hope Medical Center.
NCT00544908 is a Phase 2 study that was terminated before completion, run by City of Hope Medical Center. The registered enrollment target is 7 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (95% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00544908, a Phase 2 study, was terminated before completion, sponsored by City of Hope Medical Center.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 7 participants
- Enrollment target
Study Summary
RATIONALE: Dasatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase II trial is studying how well dasatinib works in treating patients with stage IV pancreatic cancer.
Primary Outcome
Progressive disease - appearance of one or more new lesions. Unequivocal progression of existing non-target lesions. Although a clear progression of non-target lesions only is exceptional, in such circumstances, the opinion of the treating physician should prevail and the progression status should be confirmed later on by a review panel (or study chair/primary investigator).
Interventions
- OTHER laboratory biomarker analysis
- DRUG dasatinib
- OTHER immunohistochemistry staining method
- PROCEDURE quality-of-life assessment
- OTHER immunoenzyme technique
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2007-09 |
| Phase | Phase 2 |
Why NCT00544908 stopped before completion
NCT00544908 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 7 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (95% lower).
The record links to 0 conditions, and to 5 interventions - of which laboratory biomarker analysis is the first listed.
NCT00544908 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00544908 about?
NCT00544908 is a clinical study titled "Dasatinib in Treating Patients With Stage IV Pancreatic Cancer". RATIONALE: Dasatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase II trial is studying how well dasatinib works in treating patients with stage IV pancreatic cancer.
What is the current status of trial NCT00544908?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 7 participants. The study started on 2007-09.
What interventions are being tested in trial NCT00544908?
The interventions under investigation include: laboratory biomarker analysis (OTHER), dasatinib (DRUG), immunohistochemistry staining method (OTHER), quality-of-life assessment (PROCEDURE), immunoenzyme technique (OTHER).
Who is sponsoring clinical trial NCT00544908?
This trial is sponsored by City of Hope Medical Center, which has 582 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00544908's enrollment target sits among peer trials
7 1996th of 2000 higher than 5 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia